Status:
ACTIVE_NOT_RECRUITING
A Study of the Effectiveness of Cabozantinib in Combination With Nivolumab as First-line Treatment of Advanced Renal Cell Carcinoma (aRCC) in Adults
Lead Sponsor:
Ipsen
Conditions:
Advanced Renal Cell Carcinoma
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to collect data to describe the safety and effectiveness of cabozantinib and nivolumab in combination as a first-line treatment in adults with aRCC with clear cell-compone...
Eligibility Criteria
Inclusion
- Participants with diagnosis of aRCC with clear-cell component
- Participants with no prior systemic treatment for aRCC with clear-cell component;
- Physician-initiated decision to treat with cabozantinib and nivolumab in combination (prior to study enrolment), according to Cabometyx® and Opdivo® approved local labels;
Exclusion
- Current participation in an investigational program with any intervention which could possibly interfere the treatment and impact this study;
- History of allergy or hypersensitivity to Cabometyx® or Opdivo® components.
Key Trial Info
Start Date :
September 26 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 30 2026
Estimated Enrollment :
311 Patients enrolled
Trial Details
Trial ID
NCT05361434
Start Date
September 26 2022
End Date
November 30 2026
Last Update
January 5 2026
Active Locations (66)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU St Pierre & Brugmann
Brussels, Belgium
2
Jessa Ziekenhuis
Hasselt, Belgium
3
CHU Namur Mont-Godinne
Yvoir, Belgium
4
Centre Hospitalier Universitaire (CHU) de Angers
Angers, France